亮氨酸竞争性阻断犬尿氨酸入脑并预防脂多糖诱导的小鼠抑郁样行为
该研究在小鼠中检验亮氨酸能否通过竞争血脑屏障LAT1转运体阻止犬尿氨酸入脑,从而预防炎症诱导的抑郁样行为。结果显示亮氨酸降低脑内犬尿氨酸水平、阻断脂多糖诱导的抑郁样行为并在对照小鼠中具有抗抑郁样效应,且不影响疾病行为和神经炎症。体外血脑屏障模型证实犬尿氨酸与亮氨酸在LAT1上竞争入脑,而外排为主要方向且不依赖LAT1。
要点
- 亮氨酸可降低脑内犬尿氨酸水平并阻断脂多糖诱导的小鼠抑郁样行为。
- 亮氨酸在对照小鼠中具有抗抑郁样效应,但不影响疾病行为和神经炎症。
- 体外血脑屏障模型证实犬尿氨酸与亮氨酸在LAT1上竞争入脑转运。
核心结论
- 亮氨酸对炎症诱导的抑郁具有抗抑郁特性,其机制之一是阻断犬尿氨酸进入大脑。
研究设计与样本
- 小鼠实验:腹腔注射脂多糖(LPS,0.83 mg/kg)或生理盐水,并在LPS前和LPS后6小时给予L-亮氨酸(50 mg/kg,腹腔注射)或溶剂。
- 行为学检测采用强迫游泳试验中不动时间增加和蔗糖偏好降低评估抑郁样行为。
- 另设实验:在小鼠注射犬尿氨酸(33 mg/kg,腹腔注射)前立即注射L-亮氨酸(300 mg/kg,腹腔注射),3小时后测量脑内犬尿氨酸和抑郁样行为。
- 采用体外血脑屏障模型验证犬尿氨酸与亮氨酸在LAT1上的竞争性转运。
主要发现
- 亮氨酸降低脑内犬尿氨酸水平,阻断LPS诱导的抑郁样行为,并在对照小鼠中具有抗抑郁样效应。
- 亮氨酸对疾病行为和神经炎症本身没有影响。
- 亮氨酸阻止外源性犬尿氨酸进入大脑,并消除强迫游泳试验中不动时间增加所反映的抑郁样行为。
- 体外血脑屏障模型证实犬尿氨酸与亮氨酸在氨基酸转运体LAT1水平上竞争入脑摄取。
- 外排是犬尿氨酸转运的主要方向,且在很大程度上不依赖LAT1和亮氨酸。
临床怎么用
- 提示亮氨酸可能通过阻断犬尿氨酸入脑来预防炎症相关抑郁,为干预策略提供潜在靶点。
- 机制上强调血脑屏障LAT1转运体在犬尿氨酸入脑中的竞争性调控作用。
局限性
- 研究为小鼠实验,结果向人类临床转化需进一步验证。
- 原文未报告样本量、置信区间、P值等统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammation activates indoleamine 2,3-dioxygenase (IDO) which metabolizes tryptophan into kynurenine. Circulating kynurenine is transported into the brain by the large amino transporter LAT1 at the level of the blood-brain barrier. We hypothesized that administration of leucine that has a high affinity for LAT1 should prevent the entry of kynurenine into the brain and attenuate the formation of neurotoxic kynurenine metabolites. To test whether leucine could prevent inflammation-induced depression-like behavior, mice were treated with lipopolysaccharide (LPS, 0.83 mg/kg IP) or saline and treated with L-leucine (50 mg/kg, IP) or vehicle administered before and 6 h after LPS. Depression-like behavior was measured by increased duration of immobility in the forced swim test and decreased sucrose preference. Leucine decreased brain kynurenine levels, blocked LPS-induced depression-like behavior and had antidepressant-like effects in control mice. Leucine had no effect of its own on sickness behavior and neuroinflammation. To confirm that leucine acts by interfering with the transport of kynurenine into the brain, mice were injected with L-leucine (300 mg/kg, IP) immediately before kynurenine (33 mg/kg IP) and brain kynurenine and depression-like behavior were measured 3 h later. Leucine did prevent the entry of exogenous kynurenine into the brain and abrogated depression-like behavior measured by increased duration of immobility in the forced swim test. Additional experiments using an in vitro model of the blood-brain barrier confirmed that kynurenine competes with leucine at the level of the amino acid transporter LAT1 for brain uptake. These experiments also revealed that efflux was the dominant direction of kynurenine transport and was largely independent of LAT1 and leucine, which explains why leucine could block brain uptake of kynurenine without affecting brain clearance. These findings demonstrate that leucine has antidepressant properties vis-à-vis inflammation-induced depression and one mechanism for this is by blocking the ability of kynurenine to enter the brain.
引用
- Walker AK, Wing EE, Banks WA, et al. Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice. Mol Psychiatry. 2018. PMID: 29988087. doi:10.1038/s41380-018-0076-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。